Centinel Spine has obtained approval from the US Food and Drug Administration (FDA) for its Stalif Midline, Midline II and Midline II-Ti (Ti-active) devices for use with allogeneic bone graft in lumbar spinal fusion procedures.
In late 2014, the company received allogeneic clearance for its Stalif C and Stalif C-Ti devices for use in cervical fusion (ACDF) procedures.
MIDLINE II is said to offer traditional Stalif benefits of compressive fixation with the horizontal inclination of it lag screws.
Centinel Spine chairman and CEO John Viscogliosi said: "Surgeons can feel confident that if they choose allogeneic tissue or autograft bone they are using all our Integrated Interbody devices on-label in either anterior cervical or anterior lumbar spinal fusion (ALIF) procedures."
The firm said that all of its Stand-Alone, No-Profile and Integrated Interbody systems are indicated for use with both autograft and allogeneic bone graft in lumbar and cervical spinal fusion procedures.
Having begun operations in 2008, Centinel Spine was established through the merger-acquisition of two medical firms Raymedica and Surgicraft.